Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organisation (CDMO), has announced the resignation of Amrut Medhekar, Chief Executive Officer for its CDMO business, effective July 15, 2025. The company confirmed the development through a regulatory filing following the Board of Directors’ meeting on 26 May 2025.

“In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held on 26th May, 2025 has accepted resignation of Mr. Amrut Medhekar, CEO (CDMO) of the Company w.e.f 15.07.2025,” Akums stated in a BSE filing. Medhekar’s exit comes as he plans to explore new professional avenues.

The announcement comes alongside the release of Akums’ consolidated financial results for Q4 and FY25, which indicate sustained momentum and a renewed thrust on global expansion.

Q4 and FY25: A Year of Growth and Strategic Investments

For the quarter ending March 31, 2025, Akums reported consolidated revenue of ₹1,073 crore, registering a healthy 12.4% year-on-year growth. The company posted an EBITDA margin of 10.4% for the quarter, driven by strong operational performance and a refined product mix.

For the full fiscal year FY25, Akums clocked a total income of ₹4,170 crore. The adjusted EBITDA margin for the year stood at 12.3%, a modest improvement of 7 basis points compared to the previous year. The CDMO vertical continued to be the company’s growth engine, contributing approximately 78% to total turnover with a robust EBITDA margin of 14.1%.

Global Expansion and Infrastructure Scaling

A landmark achievement for the company this year was the signing of a contract valued at approximately €200 million for the supply of pharmaceutical products to regulated European markets. Commercial supply under this agreement is expected to commence in 2027, significantly strengthening Akum’s international presence.

To support this expansion and improve manufacturing readiness, the company invested ₹272 crore in capital expenditure in FY25, bolstering its annual production capacity to 49.6 billion units. Akums also ramped up its innovation capabilities, allocating ₹130 crore to R&D,  more than 3% of its revenue, reflecting a 16% increase over FY24.

The company now boasts 973 DCGI approvals and a product portfolio exceeding 4,000 commercialised formulations across 60+ dosage forms and multiple therapeutic areas.

Segmental Highlights

Akums’ domestic branded formulation business reported 9% year-on-year growth, while the international branded formulation segment saw a 14% rise. However, trade generics and APIs remained in operational loss territory. The company has stated that measures are underway to address these challenges in the coming fiscal.

Despite a flat YoY revenue at the group level due to industry-wide pricing pressure and volume softness in APIs, Akums remains bullish on its long-term trajectory, focusing on quality, differentiated offerings, and global market penetration.

Also Read :- MedLern and OMNI Hospitals Collaborate to Strengthen Workforce Training Across Five Key Facilities

Leadership Speaks: A Vision for Global CDMO Leadership

Commenting on the company’s FY25 performance, Sanjeev Jain, Managing Director, Akums Drugs and Pharmaceuticals Ltd., said:
“As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums’ global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies.”

Adding to this perspective, Sandeep Jain, Managing Director, Akums Drugs and Pharmaceuticals Ltd., stated:
“It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals—operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organisation.“

As Akums charts its next phase of growth with a sharpened focus on innovation, capacity expansion, and global markets, the leadership transition is set to bring new momentum in shaping the future of one of India’s most prominent CDMO players.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!